Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 3.04 0.00 (0.00%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares rise over 7% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session.
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Shares of Pluristem Therapeutics Inc. Soars by 38.81% for the Week  Ashburn Daily
Pluristem Therapeutics (PSTI) Reports Data from Phase I/II PLX-PAD Trail
Share Price of Pluristem Therapeutics Inc. Rally 3.93%
Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) rose by 3.93% in the past week and 4.3% for the past 4 weeks. For the past week, the counter has outperformed the S&P 500 by 1.87% and the outperformance increases to 0.44% for the past 4 weeks.
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4%
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares rise more than 20% on the day.
Stocks Underperform for the Week: GenMark Diagnostics Inc , Pluristem ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has dropped 3.94% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 9.39% in the past 4 weeks.
Pluristem surges on bullish research report (PSTI)
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Upgraded To A Buy with A $21 ...  USMarketsDaily (blog)
Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report?
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects.
Related articles »  
Pluristem Therapeutics Inc. Analyst Rating Update
Analysts at Zacks have given a Outperform rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a rating of 1. The counter has received an average rating of 1.67 from 3 brokerage firms.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Update: Pluristem Therapeutics ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Update based on the information released on Wednesday, Feb 18th , Pluristem Therapeutics announced the positive results of a recently completed trial conducted by the U.S.
Significant Findings in U.S. National Institutes of Health's Trial of ...  Digital Journal
Pluristem Therapeutics Inc. Receives Average Target Price of $4
Pluristem Therapeutics Inc. (NASDAQ:PSTI): 3 analysts have set the short term price target of Pluristem Therapeutics Inc. (NASDAQ:PSTI) at $4. The standard deviation of short term price target has been estimated at $1, implying that the actual price ...
Needham & Company LLC Lowers Pluristem Therapeutics Price Target to $4 ...  The Legacy
Pluristem Therapeutics Price Target Lowered to $4.00 at Needham & ...  Dakota Financial News